Single-dose famciclovir for the treatment of herpes labialis

Current Medical Research and Opinion

Volumn 22, Issue 9, 2006, Pages 1699-1702

  Hull, Christopher ^a   Spruance, Spotswood ^a   Tyring, Stephen ^b   Harmed, Kamal ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b University of Texas Health Science Center   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antiviral; Cold sores; Famciclovir; Herpes labialis

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BEHENYL ALCOHOL; FAMCICLOVIR; PENCICLOVIR; PLACEBO; VALACICLOVIR;

CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SELF ADMINISTRATION; HERPES LABIALIS; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE DEFICIENCY; LONG TERM CARE; PAIN; RECURRENT INFECTION; REVIEW; VIRUS REPLICATION;

2-AMINOPURINE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HERPES LABIALIS; HERPESVIRUS 1, HUMAN; HUMANS;

EID: 33749010099     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X120922     Document Type: Review

References (19)

1. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002;186(Suppl 1):S3-28
2. Spruance SL. Herpes simplex labialis. In: Sacks SL, Straus SE, Whitley RJ, Griffiths PD (eds). Clinical Management of Herpes Viruses. Amsterdam, Netherlands: IOS Press, 1995, pp.3-42
3. Spruance SL. The natural history of recurrent oral-facial herpes simplex virus infection. Seminars Dermatol 1992;11:200-6
4. Spruance SL, Kriesel JD. Treatment of herpes simplex labialis. Herpes 2002;9:64-9
5. Spruance SL, Rea TL, Thoming C, et al. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA 1997;277:1374-9
6. Spruance SL, Jones TM, Blatter MM, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003;47:1072-80
7. Earnshaw DL, Bacon TH, Darlison SJ, et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36:2747-57
8. Vere Hodge RA, Sutton D, Boyd MR, et al. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989;33:1765-73
9. Spruance SL, Freeman DJ. Topical treatment of cutaneous herpes simplex virus infections (review article). Antiviral Res 1990;14:305-21
10. Raborn GW, Martel AY, Lassonde M, et al. Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. J Am Dent Assoc 2002;133:303-9
11. Spruance SL, Nett R, Marbury T, et al. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother 2002;46:2238-43
12. Spruance SL, Stewart JC, Rowe NH, et al. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990;161:185-90
13. Spruance SL, Overall JC, Jr, Kern ER, et al. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med 1977;297:69-75
14. Spruance SL, Wenerstrom G. Pathogenesis of recurrent herpes simplex labialis, IV: maturation of lesions within 8 hours after onset and implications for antiviral treatment. Oral Surg Oral Med Oral Pathol 1984;58:667-71
15. Spruance SL, Hill J. Clinical significance of antiviral therapy for episodic treatment of herpes labialis: exploratory analyses of the combined data from two valaciclovir trials. J Antimicrob Chemother 2004;53:703-7
16. Spruance SL, Rowe NH, Raborn GW, et al. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis 1999;179:303-10
17. Pue MA, Benet MA. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 1993;4(Suppl 1):47-55
18. Spruance SL, Bodsworth N, Resnick H, et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006;55:47-53
19. Sacks SL, Thisted RA, Jones TM, et al. Docosanol 10% Cream Study Group. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol 2001;45:222-30